ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO622

Prevalence and Outcomes Associated with NSAID Use in Patients with CKD

Session Information

  • Pharmacology
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 1700 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Chan, Samantha L., University of California San Diego, San Diego, California, United States
  • Macedo, Etienne, University of California San Diego, San Diego, California, United States
  • Trzebinska, Danuta, University of California San Diego, San Diego, California, United States
  • Awdishu, Linda, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences , La Jolla, California, United States

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with an increased risk of incident acute kidney injury and chronic kidney disease (CKD). The effect of NSAIDs on the rate of CKD progression is still uncertain. The purpose of this study is to measure the prevalence of NSAID use in CKD patients under the care of a nephrologist compared to a primary care physican (PCP) and evaluate the impact of NSAID use on CKD progression.


This is a single center, retrospective study of patients with CKD stage 3 to 5 over a 1 year period. Patients 18 years or older with GFR < 60 mL/min (2 occasions), an office visit with nephrologist or PCP and an active NSAID prescription were included. We excluded hospitalized patients, transplant recipients, AKI episodes or dialysis dependency. We evaluated the change in GFR pre and post NSAID prescription over 1 year compared to non-NSAID users and compared nephrology to PCP care. Multivariate logistic regression identified potential co-variates of GFR change.


Of the 2,157 patients included in the study, 12.2% had an NSAID prescription; 9.6% vs. 15% for patients receiving care from a nephrologist or PCP (p<0.001). Table 1 describes baseline demographics. GFR change was -3.9 vs. -3.7 mL/min/1.73 m2 (p=NS) for NSAID users and non-users, respectively. In patients managed by a nephrologist, GFR change was -4.94 vs. -4.21 mL/min/1.73m2 (p=NS) in users and non-users, while GFR change for patients managed by a PCP was -3.18 vs. -3.05 mL/min/1.73m2 (p=NS) in users and non-users, respectively. Age (p<0.001), diabetes (p=0.02) and hepatitis C (p=0.001) were significantly associated with GFR change.


NSAIDs are prescribed to more than one out of every ten patients with CKD; more often by PCPs than nephrologists. Over 1 year, there was no statistically significant GFR change for NSAID users compared to non-users. Further long term studies are warranted to confirm safety of this medication class.

Baseline Demographics
(n = 1,123)
Primary Care
(n = 1,034)
Age, mean (IQR)64 (56-75)73 (65-82)
Male gender, n(%)619 (55.1)539 (52.1)
Race, n(%)
African American
American Indian or Alaskan

113 (10.1)
4 (0.4)
154 (13.7)
207 (18.4)
19 (1.7)
626 (55.7)

50 (4.8)
4 (0.4)
115 (11.1)
116 (11.2)
8 (0.8)
741 (71.7)
Comorbidities, n(%)
Chronic lung disease
Peripheral artery disease
Hepatitis C
Cerebrovascular disease
77 (6.9)
825 (73.5)
20 (1.8)
57 (5.1)
335 (29.8)
23 (2)
49 (4.4)
3 (0.3)
11 (1.1)
752 (72.7)
13 (1.3)
54 (5.2)
269 (26)
19 (1.8)
18 (1.7)
9 (0.9)
eGFR (mL/min/1.73m2), n(%)
< 15
631 (63)
239 (21.3)
176 (15.7)
918 (88.8)
75 (7.3)
41 (4)
Baseline eGFR (mL/min/1.73 m2), mean (IQR)34 (23-47)45 (40-54)